Berzosertib is under clinical development by Merck and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Berzosertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Berzosertib overview

Berzosertib (VX-970) is under development for the treatment of solid tumors including squamous non-small cell lung cancer, osteosarcoma, leiomyosarcoma, metastatic hormone refractory (castration-resistant, androgen-independent) prostate cancer, head and neck squamous cell carcinoma, neuroendocrine tumors, peritoneal cancer, fallopian tube cancer, metastatic ovarian cancer, adenocarcinoma or squamous cell carcinoma of the oesophagus, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), middle east respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). The drug candidate is administered through intravenous route. VX-970 is an ATR kinase inhibitor. It is a new chemical entity (NCE). The drug candidate was also under development for the treatment of urothelial carcinoma of pelvic and bladder, small cell lung cancer , ureter cancer, colorectal cancer, non-metastatic and metastatic triple negative breast cancer (estrogen receptor, progesterone receptor, HER2 negative), pancreatic cancer and gastroesophageal junction adenocarcinoma.

Merck overview

Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops, and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

For a complete picture of Berzosertib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.